| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
KL001 targets cryptochrome proteins CRY1 and CRY2, preventing their degradation by the ubiquitin–proteasome pathway. This lengthens the circadian period and modulates rhythmic gene expression. KL001 may be used to control fasting hormone-induced gluconeogenesis. It is a blue light-sensitive flavoprotein involved in regulating circadian rhythms in animals and plants.
|
|---|---|
| ln Vitro |
KL001 (0.03-71 μM) induces a controlled circadian manner, resulting in a longer period and smaller amplitude of circadian rhythms in stable U2OS reporter cell lines expressing Bmal1-dLuc or Per2-dLuc [1). Without altering their basal expression in primary mouse hepatocytes, KL001 (2-8 μM; 18 hours) inhibits the glucagon-dependent induction of Pck1 and G6pc genes [1].
In vitro, KL001 prevents ubiquitin-dependent degradation of CRY, resulting in lengthening of the circadian period. Treatment with KL001 promotes proliferation, migration, and tubular formation of HUVECs. It was identified from an unbiased cell-based circadian screen in human osteosarcoma U2OS cells harboring a Bmal1-dLuc luciferase reporter. |
| ln Vivo |
In vivo, KL001 has been studied for its effects on circadian rhythms and metabolism. It may be used to control fasting hormone-induced gluconeogenesis. It holds therapeutic potential for sleep disorders, metabolic diseases, and mood regulation.
|
| Enzyme Assay |
In vitro binding assays for KL001 typically measure its interaction with CRY1 and CRY2. Binding affinity is determined using surface plasmon resonance or isothermal titration calorimetry. The compound's ability to prevent CRY ubiquitination and degradation is assessed.
|
| Cell Assay |
Cell-based assays for KL001 involve treating cells with the compound and measuring CRY protein levels, circadian rhythm parameters, and gene expression. Cells harboring a Bmal1-dLuc luciferase reporter are used to monitor circadian rhythms. HUVEC proliferation, migration, and tubular formation are assessed.
|
| Animal Protocol |
In vivo animal studies for KL001 typically involve administration to animal models to study circadian rhythms and metabolism. The compound's effects on circadian period, glucose metabolism, and behavior are assessed. Its potential for controlling gluconeogenesis is evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of KL001 have not been extensively characterized. The compound is typically dissolved in DMSO for in vitro studies. Its absorption, distribution, metabolism, and excretion have not been fully studied. It has a molecular weight of 398.48.
|
| Toxicity/Toxicokinetics |
The toxicological profile of KL001 has not been extensively characterized. As a research compound, it should be handled with appropriate safety precautions. It is a first-in-class CRY stabilizer.
|
| References | |
| Additional Infomation |
KL001 is a research tool for studying circadian rhythms, cryptochrome function, and clock-based therapeutics. It is not approved for therapeutic use. The compound is valuable for investigating the role of the circadian clock in health and disease. It is a novel and specific small molecule activator of cryptochrome.
|
| Molecular Formula |
C21H22N2O4S
|
|---|---|
| Molecular Weight |
398.477
|
| Exact Mass |
398.13
|
| Elemental Analysis |
C, 63.30; H, 5.57; N, 7.03; O, 16.06; S, 8.05
|
| CAS # |
309928-48-1
|
| PubChem CID |
2888648
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
578.1±60.0 °C at 760 mmHg
|
| Flash Point |
303.4±32.9 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.642
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
600
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])[H])(N(C([H])([H])C1=C([H])C([H])=C([H])O1)C([H])([H])C([H])(C([H])([H])N1C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12)O[H])(=O)=O
|
| InChi Key |
OQAFDLPAPSSOHY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22N2O4S/c1-28(25,26)22(15-17-7-6-12-27-17)13-16(24)14-23-20-10-4-2-8-18(20)19-9-3-5-11-21(19)23/h2-12,16,24H,13-15H2,1H3
|
| Chemical Name |
N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide
|
| Synonyms |
KL 001; KL-001; KL001
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~12.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5095 mL | 12.5477 mL | 25.0954 mL | |
| 5 mM | 0.5019 mL | 2.5095 mL | 5.0191 mL | |
| 10 mM | 0.2510 mL | 1.2548 mL | 2.5095 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
